Tiger Brokers

Boston Scientific Continues to See Competitive Pressures, Oppenheimer Says

MT Newswires Live
Jul 27

Boston Scientific (BSX) continues to see competitive pressures that could have weighed on the company's Q2 results, Oppenheimer said in a Monday note.

The company is set to release its Q2 results on Wednesday and Oppenheimer said it is "widely expected" to be a soft quarter for Boston Scientific's electrophysiology and Watchman products. The brokerage said it lowered its Q2 forecasts for both product segments.

In addition, Boston Scientific's long-range plan remains as a "critical overhang" on the company's stock, Oppenheimer said.

The investment firm still noted Boston Scientific's outperformance over the past years, mainly driven by the growth of its electrophysiology business and robust pipeline.

Oppenheimer lowered its price target on Boston Scientific to $85 from $90, with an outperform rating.

Price: 45.94, Change: +1.69, Percent Change: +3.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10